Additional Ring Containing Patents (Class 546/337)
  • Patent number: 8263627
    Abstract: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: September 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James C. Barrow, Thomas S. Reger, Zhi-Qiang Yang
  • Publication number: 20120226047
    Abstract: The present invention relates to the use of certain high potency savory (‘umami’) taste modifiers, as savory flavoring agents and/or enhancers of monosodium glutamate, for the preparation of foods, beverages, and other comestible compositions, and to processes for preparing food flavorant compositions for use in the preparation of comestible food and drink.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 6, 2012
    Applicant: SENOMYX, INC.
    Inventors: Rhondi SHIGEMURA, Qing Chen, Vincent Darmohusodo, Aaron R. Dean
  • Publication number: 20120225912
    Abstract: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer.
    Type: Application
    Filed: July 30, 2010
    Publication date: September 6, 2012
    Inventors: Jack Tuszynski, Jonathan Y. Mane, John Torin Huzil, Boguslaw Tomanek, Dorota Bartusik
  • Publication number: 20120202817
    Abstract: A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R1 and R2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R1 and R2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Honda, Hisashi Tajima, Yoshimasa Sasabuchi, Kenji Kawashima, Kazuyoshi Okamoto, Minoru Yamamoto, Masakazu Ban
  • Publication number: 20120202777
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives of Formula I, wherein the variables G, T, D, L, A, X, R1 and R2 are as described hereinabove, and their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Application
    Filed: October 4, 2010
    Publication date: August 9, 2012
    Inventors: Matthew Frank Brown, Anthony Marfat, Michael Joseph Melnick, Usa Reilly
  • Publication number: 20120196838
    Abstract: The invention relates to certain compounds according to Formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders and immune disorders.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 2, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Junyi Zhang, Shoujun Chen, Lijun Sun
  • Publication number: 20120165539
    Abstract: The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and Xi and X2 independently of each other represent C and form part of an additional 6-membered aromatic ring; R1 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyallyl, or alkylcarbonyl, all of which are optionally substituted; R2 and R3 independently represent hydrogen, —CH2—C(O)NR—R?, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, hydroxyalkyl, heterocycloalkenyl, alkylaryl, alkylalkoxycarbonyl, alkylcarbonyloxy, or alkoxyalkyl, all of which are optionally substituted; R11 represents hydrogen, halogen, cyano, amino, alkoxy or alkylamino, X1-X5 represent —CH— or N, including N-oxides, enantiomers and diastereomers; and pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 28, 2012
    Inventors: Jakob FELDING, Simon Feldbæk NIELSEN
  • Patent number: 8207194
    Abstract: A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R1 and R2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R1 and R2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: June 26, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Takahiro Honda, Hisashi Tajima, Yoshimasa Sasabuchi, Kenji Kawashima, Kazuyoshi Okamoto, Minoru Yamamoto, Masakazu Ban
  • Patent number: 8178558
    Abstract: This invention relates to novel substituted pyridylmethyl bicyclocarboxamide compounds and to their use in therapy. These compounds are particularly useful as modulators of the VR1 (Type I Vanilloid) receptor, and are thus useful for the treatment of pain, neuralgia, neuropathies, nerve injury, burns, migraine, carpal tunnel syndrome, fibromyalgia, neuritis, sciatica, pelvic hypersensitivity, bladder disease, inflammation, or the like in mammals, especially humans.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: May 15, 2012
    Assignee: Pfizer Inc.
    Inventors: Satoshi Nagayama, Yuji Shishido, Hirotaka Tanaka
  • Publication number: 20120116075
    Abstract: An acrylamide derivative represented by formula (I), pharmaceutically acceptable salts and solvates thereof, as well as a medicament containing said acrylamide derivative or its pharmaceutically acceptable salts as the active ingredient, which can be used to treat disorders associated with tyrosine kinase especially Bcr-Abl, including proliferative disorders such as cancers, and inflammation and the like are provided.
    Type: Application
    Filed: April 27, 2010
    Publication date: May 10, 2012
    Applicants: BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD, BEIJING SHIQIAO BIOPHARM CO. LTD
    Inventor: Shuping Sun
  • Publication number: 20120114633
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Application
    Filed: April 6, 2010
    Publication date: May 10, 2012
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams
  • Publication number: 20120094980
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 19, 2012
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F.T. Koehler
  • Patent number: 8158825
    Abstract: The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: April 17, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jonathan Grimm, Paul Harrington, Richard Heidebrecht, Jr., Thomas Miller, Karin Otte, Phieng Siliphaivanh, David Sloman, Matthew Stanton, Kevin Wilson, David Witter, Solomon Kattar, Paul Tempest
  • Patent number: 8148536
    Abstract: The present invention relates to the use of certain high potency savory (“umami”) taste modifiers, as savory flavoring agents and/or enhancers of monosodium glutamate, for the preparation of foods, beverages, and other comestible compositions, and to processes for preparing food flavorant compositions for use in the preparation of comestible food and drink.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: April 3, 2012
    Assignee: Senomyx, Inc.
    Inventors: Rhondi Shigemura, Qing Chen, Vincent Darmohusodo, Aaron R. Dean
  • Publication number: 20120071520
    Abstract: The present invention relates to polymorphic forms and solvates of 2?-{[2-(4-methoxy-phenyl)-acetylamino]-methyl]}-biphenyl-2-carboxylic acid (2-pyhdin-3-yl-ethyl)-amide, processes for their preparation and their use, in particular for the preparation of medicaments.
    Type: Application
    Filed: May 26, 2010
    Publication date: March 22, 2012
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Norbert Nagel, Harald Berchtold, Michael Schur, Dirk Hoerstermann
  • Patent number: 8133907
    Abstract: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12; R9 is selected from H —NR13C(O)R14 and —C(O)NR10R11; R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: March 13, 2012
    Assignee: Eli Lilly and Company
    Inventors: Larry Chris Blaszczak, Brian Michael Mathes, Shon Roland Pulley, Michael Alan Robertson, Scott Martin Sheehan, Qing Shi, Brian Morgan Watson, Michael Robert Wiley
  • Publication number: 20120053200
    Abstract: The present invention relates to N-1-Benzyl-2-hydroxy-3-(hetero)arylamino-propyl)-isophthalamides of formula I having BACE2 inhibitory activity and their use as therapeutically active substances, their manufacture and pharmaceutical compositions. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. type 2 diabetes.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 1, 2012
    Inventors: Harald Mauser, Matthias Nettekoven, Sébastien Schmitt
  • Patent number: 8124605
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 28, 2012
    Assignee: Kinex Pharmaceuticals, LLC
    Inventor: David G. Hangauer, Jr.
  • Patent number: 8124587
    Abstract: 2-(Aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa are provided. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: February 28, 2012
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Torsten Steinmetzer, Daniel Doennecke, Andrea Schweinitz, Anne Stuerzebecher, Joerg Stuerzebecher
  • Publication number: 20120046293
    Abstract: The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: October 10, 2011
    Publication date: February 23, 2012
    Applicant: Merck Frosst Canada Ltd.
    Inventors: CHRISTOPHER I. BAYLY, Austin C. Chen, Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Dwight MacDonald, Daniel McKay, David A. Powell, Erich L. Grimm
  • Publication number: 20120040986
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Inventors: Bernd RIEDL, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, Mary-Katherine MONAHAN, Reina NATERO, Joel RENICK, Robert N. SIBLEY
  • Publication number: 20120028995
    Abstract: The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as well as in the stimulation of anti-inflammatory cytokine production in vitro and in vivo. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
    Type: Application
    Filed: July 19, 2011
    Publication date: February 2, 2012
    Applicant: IMTM GMBH
    Inventors: Siegfried ANSORGE, Ute BANK, Anke HEIMBURG, Heiko JULIUS, Karsten NORDHOFF, Michael TAEGER
  • Patent number: 8106073
    Abstract: The invention provides a compound of formula (I) as defined in the specification, a process for its preparation, pharmaceutical compositions containing it, a process for preparing the pharmaceutical composition, and its use in therapy.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 31, 2012
    Assignee: AstraZeneca AB
    Inventors: Simon David Guile, Toby Thompson
  • Publication number: 20120004243
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: April 5, 2011
    Publication date: January 5, 2012
    Applicant: AstraZeneca AB
    Inventors: Dearg Sutherland Brown, John Graham Cumming, Ian Alun Nash
  • Patent number: 8084616
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: December 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • Patent number: 8067608
    Abstract: Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: November 29, 2011
    Assignee: The Johns Hopkins University
    Inventors: Philip A. Beachy, James K. Chen, Anssi J. Taipale
  • Publication number: 20110281872
    Abstract: The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.
    Type: Application
    Filed: March 11, 2011
    Publication date: November 17, 2011
    Applicant: Kinex Pharmaceuticals, LLC
    Inventors: David G. Hangauer, JR., Michael J. Ciesielski, Robert A. Fenstermaker
  • Publication number: 20110275797
    Abstract: An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or the like; R2 represents a hydrogen atom or the like; R3 represents an optionally substituted aryl group or the like; X1 represents a carbonyl group; X2 represents a bonding hand; X3 represents a bonding hand; X4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.
    Type: Application
    Filed: January 29, 2010
    Publication date: November 10, 2011
    Applicant: Toyama Chemical Co., Ltd.
    Inventors: Junichi Yokotani, Arihiro Takatori, Yukie Tada, Minori Yanai, Hiroshi Kato, Yoichi Taniguchi, Chiharu Tanabe
  • Patent number: 8053439
    Abstract: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: November 8, 2011
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Nam-Song Choi, Young-Mi Kim, Young-Hoon Kim, Jae-Kwang Lee, In-Taek Lim, Ho-Jin Choi, Hyun-Mo Yang, Seung-Kee Moon, Soo-Jin Kim, Hyun-Jung Yu, Jae-Su Shin, Young-Min Kwon, Sung-Sook Lee, Soon-Kil Ahn, Sun-Ju Kong
  • Publication number: 20110263564
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: October 29, 2009
    Publication date: October 27, 2011
    Applicant: Sirtris Pharmaceuticals, Inc.
    Inventors: Radha Narayan, Jeremy S. Disch, Robert B. Perni, Chi B. Vu
  • Publication number: 20110251204
    Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
    Type: Application
    Filed: October 4, 2010
    Publication date: October 13, 2011
    Inventors: Yingzhi Bi, Carolyn Diane Dzierba, Joanne J. Bronson, Cynthia Fink, Michael Green, David Kimball, John E. Macor, Soojin Kwon, Yulian Zhang, Greg Zipp
  • Publication number: 20110251206
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • Publication number: 20110251196
    Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
    Type: Application
    Filed: October 5, 2010
    Publication date: October 13, 2011
    Inventors: Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
  • Publication number: 20110245250
    Abstract: Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs thereof wherein: Ar1 and Ar2 are aryl or heteroaryl; a is 0 to 5; R1 is alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monoalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino or cyano and, where a is greater than 1, each substituent R1 may be the same or different; b is 0 to 5; R2 is alkyl, halogen, haloalkyl, haloalkoxy, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monoalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino or cyano and where b is greater than 1, each substituent R2 may be the same or different; V is selected from the group consisting of (CR3aR3b)pCON(R3b)X and (CR3aR3b)pN(R3b)CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z; W is selected from the group consisting of NR4a, O, S, S?O, SO2 and C(R4aR4b)2; X is hydroge
    Type: Application
    Filed: July 20, 2009
    Publication date: October 6, 2011
    Applicant: Ramot at tel-Aviv University Ltd.
    Inventors: Simon David Edwards, Meriel Ruth Kimberley, Richard Edward Armer, Nawaz Mohammed Khan
  • Publication number: 20110245504
    Abstract: The present invention pertains generally to methods of preparing certain 9-(arylalkyl)-1,2,3,4-tetrahydro-?-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-?-carboline compounds.
    Type: Application
    Filed: December 11, 2009
    Publication date: October 6, 2011
    Inventors: Craig Williamson, John Mervyn David Storey
  • Publication number: 20110237578
    Abstract: Compounds are provided according to formula (I), where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: September 14, 2009
    Publication date: September 29, 2011
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Publication number: 20110224210
    Abstract: The invention relates to novel bis-amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Application
    Filed: November 18, 2009
    Publication date: September 15, 2011
    Inventors: Hamed Aissaoui, Christoph Boss, Olivier Corminboeuf, Marie-Celine Frantz, Corinna Grisostomi
  • Patent number: 8017630
    Abstract: Novel cyclohexylacetic acid compounds corresponding to formula I: processes for the production thereof, pharmaceutical compositions containing these compounds, methods of producing pharmaceutical compositions including these compounds and related methods of treating or inhibiting certain diseases or conditions.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: September 13, 2011
    Assignee: Gruenenthal GmbH
    Inventors: Claudia Hinze, Bernd Sundermann, Hans Schick, Birgitta Henkel
  • Publication number: 20110218221
    Abstract: The present invention relates to compounds represented by formula (I) or composition comprising at least one of such compounds, which are inhibitors of histone deacetylase. The detailed description of these compounds is disclosed in the Description. These compounds and the composition comprising the same may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities.
    Type: Application
    Filed: October 27, 2008
    Publication date: September 8, 2011
    Applicants: Zhejiang Hisun Pharmaceutical Co., Ltd., Central South University
    Inventors: Niefang Yu, Xiaoyu Liu, Xiaodong Hu
  • Publication number: 20110207739
    Abstract: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.
    Type: Application
    Filed: February 25, 2010
    Publication date: August 25, 2011
    Inventor: Hsu-Shan HUANG
  • Publication number: 20110207783
    Abstract: The present invention relates to acyclic amino amide renin inhibitor compounds and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: August 4, 2008
    Publication date: August 25, 2011
    Inventors: Daniel Dube, Austin Chen, Daniel J. McKay
  • Publication number: 20110207747
    Abstract: The present invention is directed to 2,5-disubstituted phenyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 26, 2009
    Publication date: August 25, 2011
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Anthony J. Roecker, John D. Schreier
  • Publication number: 20110178042
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L1-L4 A, B, R1-R4 and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.
    Type: Application
    Filed: September 1, 2009
    Publication date: July 21, 2011
    Applicant: Pfizer Inc.
    Inventors: Matthew F. Brown, Charles F. Donovan, Edmund L. Eilsworth, Denton W. Hoyer, Timothy A. Johnson, Manjinder S. Lall, Chris Lim-Berakis, Sean T. Murphy, Debra A. Sherry, Clarke B. Taylor, Joseph S. Warmus
  • Patent number: 7982045
    Abstract: Compounds of the formula I, in which R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(8), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel and antiarrythmic active compounds, in particular for the treatment and prophylaxis of atrial arrythmias, e.g. atrial fibrillation (AF), or atrial flutter.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: July 19, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Joachim Brendel, Wolfgang Schmidt, Peter Below
  • Publication number: 20110172195
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Application
    Filed: March 15, 2011
    Publication date: July 14, 2011
    Applicant: ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
  • Publication number: 20110172174
    Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 14, 2011
    Inventors: Niels H. Andersen, Jason Bowman, Alice Erwin, Eric Harwood, Toni Kline, Khisimuzi Mdluli, Simon Ng, Keith B. Pfister, Ribhi Shawar, Allan S. Wagman, Asha Yabannavar
  • Publication number: 20110166132
    Abstract: The present invention provides compounds that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: December 12, 2008
    Publication date: July 7, 2011
    Applicant: Amgen Inc.
    Inventors: Stephen A. Hitchcock, Jian J. Chen, Mqhele Vellah Ncube, Thomas Nixey, Albert Amegadzie, Roxanne Kunz, Wenyan Qian, Ning Chen, Christopher M. Tegley, Frenel F. De Morin, Chester Chenguang Yuan, Qingyian Liu, Jiawang Zhu, Tanya A.N. Peterkin, Jeffrey A. Adams, Essa Hu, Frank Chavez, JR.
  • Patent number: 7973166
    Abstract: The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I is described, as well as the process for the production of said compound, and its use as a medicament for the treatment of selected diseases.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: July 5, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Matthias Schneider, Michael Gottfried, Jens Geisler, Gabriele Winter
  • Publication number: 20110154583
    Abstract: Dyes, compositions comprising dyes and methods for using the same are provided.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 30, 2011
    Applicant: Living Proof, Inc.
    Inventors: Jana Lewis, Lorna Nagamoottoo-Casse, David Puerta
  • Patent number: RE43596
    Abstract: ?- and ?-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: August 21, 2012
    Assignee: G.D. Searle LLC
    Inventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Robert M. Heintz, Deborah E. Bertenshaw